Verrica Pharmaceuticals is a biotechnology business based in the US. Verrica Pharmaceuticals shares (VRCA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.55 – a decrease of 4.57% over the previous week. Verrica Pharmaceuticals employs 71 staff and has a trailing 12-month revenue of around $7.6 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.55 |
|---|---|
| 52-week range | $0.38 - $11.41 |
| 50-day moving average | $0.60 |
| 200-day moving average | $2.12 |
| Wall St. target price | $3.33 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.48 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.484 from 2025-04-11
| 1 week (2025-04-08) | -16.47% |
|---|---|
| 1 month (2025-03-14) | -9.87% |
| 3 months (2025-01-16) | -24.38% |
| 6 months (2024-10-16) | -67.95% |
| 1 year (2024-04-15) | -93.01% |
|---|---|
| 2 years (2023-04-14) | -92.19% |
| 3 years (2022-04-14) | 7.92 |
| 5 years (2020-04-15) | 11.13 |
| Revenue TTM | $7.6 million |
|---|---|
| Gross profit TTM | $-7,014,000 |
| Return on assets TTM | -59.89% |
| Return on equity TTM | -1546.58% |
| Profit margin | 0% |
| Book value | $-0.11 |
| Market Capitalization | $44.4 million |
TTM: trailing 12 months
We're not expecting Verrica Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Verrica Pharmaceuticals's shares have ranged in value from as little as $0.382 up to $11.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verrica Pharmaceuticals's is 1.682. This would suggest that Verrica Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Verrica Pharmaceuticals Inc. , a clinical-stage dermatology therapeutics company, engages in the development and sales of medications for the treatment of skin diseases in the United States. The company's product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co. , Ltd.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.